Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugsnews2025-05-16T16:17:20+00:00May 16th, 2025|The New York Times|
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drugnews2025-05-12T00:08:25+00:00May 12th, 2025|The New York Times|
What to Know About Eli Lilly’s Daily Pill for Weight Lossnews2025-04-17T21:24:51+00:00April 17th, 2025|The New York Times|
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycatsnews2025-04-16T14:43:02+00:00April 16th, 2025|The New York Times|
Weight Loss Drug Will Be Offered for $499 a Month for Some Patientsnews2025-03-05T19:09:26+00:00March 5th, 2025|The New York Times|
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovynews2025-02-05T19:24:38+00:00February 5th, 2025|The New York Times|
Medicare to Negotiate Lower Prices for Weight-Loss Drugsnews2025-01-17T13:56:26+00:00January 17th, 2025|The New York Times|
Drug Company to Share Revenues With Indigenous People Who Donated Their Genesnews2025-01-07T12:03:05+00:00January 7th, 2025|The New York Times|
U.S. Unveils Price Limits for 10 Costly or Common Medicationsnews2024-08-15T19:39:11+00:00August 15th, 2024|The New York Times|
U.S. Announces Prices for First Drugs Picked for Medicare Negotiationsnews2024-08-15T16:38:11+00:00August 15th, 2024|The New York Times|
